Comparing Mangoceuticals (MGRX) and The Competition

Mangoceuticals (NASDAQ:MGRX) is one of 19 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its peers? We will compare Mangoceuticals to similar businesses based on the strength of its earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and risk.

Valuation and Earnings

This table compares Mangoceuticals and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$866,792.00	-$9.21 million	-0.37
Mangoceuticals Competitors	$2.39 billion	$82.32 million	15.34

Mangoceuticals’ peers have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Mangoceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-1,053.93%	-243.34%	-200.73%
Mangoceuticals Competitors	-816.62%	-48.14%	-36.60%

Risk and Volatility

Mangoceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ peers have a beta of 3.97, indicating that their average stock price is 297% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mangoceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	0	0	0	0	N/A
Mangoceuticals Competitors	36	289	416	149	2.76

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 51.47%. Given Mangoceuticals’ peers higher possible upside, analysts clearly believe Mangoceuticals has less favorable growth aspects than its peers.

Summary

Mangoceuticals peers beat Mangoceuticals on 9 of the 10 factors compared.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.